Sensitive markers of inflammation make it possible to study the chronic process: the rise of interest in low levels of C-reactive protein

被引:28
作者
Kluft, C [1 ]
de Maat, MPM [1 ]
机构
[1] TNO, Gaubius Lab, PG, NL-2301 CE Leiden, Netherlands
关键词
C-reactive protein; inflammation; chronic;
D O I
10.1016/S1537-1891(02)00293-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Increases in baseline levels of C-reactive protein (CRP) have been consistently identified as an independent risk indicator of cardiovascular events. The measurement of the low level is robust and well established. Increases in low levels of CRP can mark low-grade continuous inflammation and hyperresponse in acute situations. In addition, CRP can exert various actions on vascular cells and activates complement thus participating in infarction pathogenesis. Various cardiovascular drugs, notably statins, can induce a marked decrease in low levels of CRP, which is indicative of their beneficial effect on inflammation. Future studies need to demonstrate whether increases in baseline levels of CRP can become a useful practical addition to risk recognition strategies and possibly may also serve as an additional surrogate endpoint in cardiovascular disease treatments. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:99 / 104
页数:6
相关论文
共 53 条
[1]   The occurrence during acute infections of a protein not normally present in the blood I. Distribution of the reactive protein in patients' sera and the effect of calcium on the flocculation reaction with C polysaccharide of pneumococcus [J].
Abernethy, TJ ;
Avery, OT .
JOURNAL OF EXPERIMENTAL MEDICINE, 1941, 73 (02) :173-182
[2]   Effect of statin therapy on C-reactive protein levels - The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study [J].
Albert, MA ;
Danielson, E ;
Rifai, N ;
Ridker, PM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (01) :64-70
[3]   Nuclear factor-κB suppressive and inhibitor-κB stimulatory effects of troglitazone in obese patients with type 2 diabetes:: Evidence of an antiinflammatory action? [J].
Aljada, A ;
Garg, R ;
Ghanim, H ;
Mohanty, P ;
Hamouda, W ;
Assian, E ;
Dandona, P .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (07) :3250-3256
[4]   Biological profiles in subjects with recurrent acute coronary events compared with subjects with long-standing stable angina [J].
Bogaty, P ;
Poirier, P ;
Simard, S ;
Boyer, L ;
Solymoss, S ;
Dagenais, GR .
CIRCULATION, 2001, 103 (25) :3062-3068
[5]   The effect of 17β-oestradiol on variables of coagulation and fibrinolysis in postmenopausal women with type 2 diabetes mellitus [J].
Brussard, HE ;
Leuven, JAG ;
Krans, HMJ ;
Kluft, C .
VASCULAR PHARMACOLOGY, 2002, 39 (03) :141-147
[6]   EFFECTS OF LIPID-BINDING PROTEINS APO-A-I, APO-A-II, BETA-2-GLYCOPROTEIN-I, AND C-REACTIVE PROTEIN ON ACTIVATION OF FACTOR-X BY TISSUE FACTOR - FACTOR-VIIA [J].
CARSON, SD ;
ROSS, SE .
THROMBOSIS RESEARCH, 1988, 50 (05) :669-678
[7]   C-REACTIVE PROTEIN INDUCES HUMAN PERIPHERAL-BLOOD MONOCYTES TO SYNTHESIZE TISSUE FACTOR [J].
CERMAK, J ;
KEY, NS ;
BACH, RR ;
BALLA, J ;
JACOB, HS ;
VERCELLOTTI, GM .
BLOOD, 1993, 82 (02) :513-520
[8]  
Cortellaro M, 2000, THROMB HAEMOSTASIS, V83, P549
[9]   Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses [J].
Danesh, J ;
Whincup, P ;
Walker, M ;
Lennon, L ;
Thomson, A ;
Appleby, P ;
Gallimore, JR ;
Pepys, MB .
BMJ-BRITISH MEDICAL JOURNAL, 2000, 321 (7255) :199-204
[10]  
de Maat M P, 2001, Ital Heart J, V2, P189